REGENERX BIOPHARM IN | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (29)

Latest Posts

About This Stock More About This Stock
RegeneRx Versus Restasis: Who Hits The $2 Billion Dry-Eye Jackpot?
Article By: Shock Exchange
Wednesday, October 4, 2017 6:29 PM EDT
A manhunt is on for the next dry-eye disruptor. RGRX and ALDX are two candidates. RGRX just completed Phase 3 testing. Its drug has shown success in head-to-head comparisons with Restasis and Xiidra. Will RGRX hit the dry-eye jackpot?
In this article: RGRX, ALDX, AGN Also: SHPG
Week In Review: Novartis Opens $1 Billion Shanghai R&D Center
Article By: ChinaBio® Today
Saturday, June 4, 2016 12:33 PM EDT
Novartis, a Swiss biopharma, invested $1 billion into an R&D center in Shanghai that will complement its other two major R&D hubs -- one in its Basel home and the other in Cambridge, Massachusetts.
In this article: NVS, PFE, RGRX

Latest Tweets for $RGRX

No tweets yet!